| The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series) |
16 |
| Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study |
16 |
| Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series) |
16 |
| Endothelial biomarkers in human sepsis: pathogenesis and prognosis for ARDS |
13 |
| Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension |
12 |
| Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease |
11 |
| Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI) |
11 |
| COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series) |
11 |
| Levosimendan in pulmonary hypertension and right heart failure |
11 |
| Pulmonary tumor thrombotic microangiopathy: a systematic review |
10 |
| Mechanosensing Piezo channels in tissue homeostasis including their role in lungs |
10 |
| Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension |
8 |
| Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series) |
7 |
| Rare variants In RNF2I a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice |
7 |
| Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension |
7 |
| Right heart in pulmonary hypertension: from adaptation to failure |
7 |
| Incidence and risk factors of chronic thromboembolic pulmonary hypertension following venous thromboembolism, a population-based cohort study in England |
6 |
| Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact |
6 |
| Alveolar capillary dysplasia with misalignment of the pulmonary veins: clinical, histological, and genetic aspects |
6 |
| Natural plant products in treatment of pulmonary arterial hypertension |
6 |
| Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure |
6 |
| The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension |
6 |
| Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE) |
6 |
| Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension |
6 |
| Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial |
6 |
| Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe |
6 |
| Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension |
6 |
| Substrate stiffness-dependent exacerbation of endothelial permeability and inflammation: mechanisms and potential implications in ALI and PH (2017 Grover Conference Series) |
6 |
| Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database |
6 |
| A multidisciplinary pulmonary embolism response team (PERT)-experience from a national multicenter consortium |
6 |
| Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension? |
6 |
| Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients |
6 |
| Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension |
5 |
| Difficulties in modelling ARDS (2017 Grover Conference Series) |
5 |
| Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension |
5 |
| Pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia: a longitudinal study |
5 |
| Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis |
5 |
| Endothelial dysfunction in pulmonary arterial hypertension: loss of cilia length regulation upon cytokine stimulation |
5 |
| Oral treprostinil use in children: a multicenter, observational experience |
5 |
| Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure |
4 |
| Drug repositioning in pulmonary arterial hypertension: challenges and opportunities |
4 |
| The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
4 |
| Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy? |
4 |
| Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension |
4 |
| Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension |
4 |
| Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
4 |
| Pulmonary hypertension subjects exhibit right ventricular transient exertional dilation during supine exercise stress echocardiography |
4 |
| Hypoxia-induced pulmonary hypertension and chronic lung disease: caveolin-1 dysfunction an important underlying feature |
4 |
| A case of reversible pulmonary arterial hypertension associated with incontinentia pigmenti |
4 |
| Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies |
4 |
